Education about Non-Alcoholic Steatohepatitis (NASH) and the Role of PPAR Agonists
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system and thus improving the lives of millions of patients worldwide.
Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in Prof. Stephen Harrison (USA) reviews current and future therapies for Non-Alcoholic Steatohepatitis (NASH). After a Prof. Maya Balakrishnan (USA) discusses the importance of the behavioural psychology in the field of 
Natural history & clinical outcomes in adults with NAFLD
The role of fatty liver disease and metabolic comorbidities in the progression on liver diseases
NASH Treatment in 2022: review of current and future therapies for non-alcoholic steatohepatitis
Psychological aspects of health behaviours in NAFLD non-alcoholic fatty liver disease
Data shows that NAFLD patients had adverse cognitive behavioural profiles and some have co-existing mental illnesses. Therefore healthcare professionals need The slide above illustrates the role of PPARα, PPARβ/δ and PPARγ as key regulators of lipid metabolism, inflammation and glucose There are many compounds in development for the management of NASH. It is very important to understand the path to Discover all about NASH, NAFLD PPAR agonists ⟶
PSYCHOLOGICAL ASPECTS OF HEALTH BEHAVIOURS IN NAFLD (NON-ALCOHOLIC FATTY LIVER DISEASE)
PPAR’S AS CRITICAL REGULATORS OF METABOLISM
PHASE 3 DEVELOPMENT
COVID-19, mortality and NAFLD
The authors estimated chronic liver disease-related mortality trends among individuals with diabetes before and during the COVID-19 pandemic.
HTN, NAFLD and mortality
The authors aimed to examine the impact of HTN on survival outcomes in a longitudinal cohort of NAFLD patients.
Fibrosis-4 index reflects right ventricular function and prognosis in HFpEF
The authors investigated the prognostic implication of the FIB-4 index regarding right ventricular dysfunction in patients with HFpEF.
NAFL: FIB-4, a strong predictor of both all-cause mortality and liver-related adverse outcomes
The authors analysed data on 30 million patients categorised into three diagnostic groups: NAFLD, NASH, and at risk of NASH.
New this week!
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital…
LATEST SCIENTIFIC ADVANCES IN NASH, NAFLD & PPAR AGONISTS
Natural history & clinical outcomes in adults with NAFLD
Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic fatty liver disease (NAFLD) with lessons from cohort studies and
The role of fatty liver disease and metabolic comorbidities in the progression on liver diseases
Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in the progression of chronic liver diseases. The key points addressed
NASH Treatment in 2022: review of current and future therapies for non-alcoholic steatohepatitis
Prof. Stephen Harrison (USA) reviews current and future therapies for Non-Alcoholic Steatohepatitis (NASH). After a focus on the pathogenesis of NASH and the different pathways
Psychological aspects of health behaviours in NAFLD non-alcoholic fatty liver disease
Prof. Maya Balakrishnan (USA) discusses the importance of the behavioural psychology in the field of non-alcoholic fatty liver disease, NAFLD.
NASH Management in 2022: benefits of lifestyle recommendations, including nutrition and exercise
Prof. Stephen Harrison (USA) discusses state of the art management of non-alcoholic steatohepatitis (NASH) in 2022. He focuses on the benefits of lifestyle recommendations, including
Getting to the Heart of NAFLD and NASH – The international CVD Perspective (part. 4)
This video presents a comprehensive review of non-alcoholic fatty liver disease (NAFLD) & non-alcoholic steatohepatitis (NASH), delivered by international experts with a multidisciplinary approach: Dr. Maarten Tushuizen, Prof. A.G
UPCOMING NASH EVENTS
AASLD THE LIVER MEETING
COMMENTED ARTICLES
Weight-loss alone may not be sufficient to reverse advanced fibrosis
Weight gain and risk of NAFLD: the Nurses’ Health Study II cohort
CATEGORIES
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES
Latest articles from PubMed
- Glycine-β-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice
- The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
- Cardiometabolic index: A new predictor for metabolic associated fatty liver disease in Chinese adults
- Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis
- Associations of lipid parameters with non-alcoholic fatty liver disease in type 2 diabetic patients according to obesity status and metabolic goal achievement
- Growing challenge of post-liver transplantation non-alcoholic fatty liver disease
- Natural flavonoids: Potential therapeutic strategies for non-alcoholic fatty liver disease
- Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide.
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES